An observational study in Ventricular Arrhythmia and Acute Myocardial Infarction (AMI), sponsored by Poitiers University Hospital. Recruiting at 8 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.
Sponsored by Poitiers University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in ST Elevation Myocardial Infarction with a site in France — 7 open to participants now, 11 under way, 5 of them phase 3. ST Elevation Myocardial Infarction · France.
Among the 49 studies in ST Elevation Myocardial Infarction with a site in France, this one is one of 2 that started in 2025, is one of 9 observational ones, reaches primary completion later than 3 of the 10 other live ones, and was the 49th registered.
855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.
Browse ST Elevation Myocardial Infarction studies →7 of the 49 studies in ST Elevation Myocardial Infarction with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Hospices Civils de Lyon · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Club Régional des Angioplasticiens de la région Centre · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 18 · Phase 4 2
First in 2006; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 340 across 298 observational studies indexed under ST Elevation Myocardial Infarction.
Median enrollment 325 across the 40 interventional studies, 1,027 across the 9 observational. Of the 34 that completed or were terminated, 6 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 49 have an industry lead sponsor. The 10 most frequent:
Poitiers University Hospital is the lead sponsor of 315 studies on the registry; 63 are open to participants now.
Poitiers University Hospital has 1 study filed under ST Elevation Myocardial Infarction — fewer than ten, so there is no comparison to draw.
2 of the studies in ST Elevation Myocardial Infarction with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07102628Phase 3Novartis PharmaceuticalsEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | 2027-01-16 |
| NCT05211401Assistance Publique - Hôpitaux de ParisRituximab in Patients With ST-elevation Myocardial Infarction | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 49 studies in ST Elevation Myocardial Infarction with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Ventricular arrhythmias are a serious complication of myocardial infarction. The aim of this study is to provide reliable data on the management and mortality associated with ventricular arrhythmia in the setting of acute myocardial infarction.
Ventricular arrhythmias remain a major complication during the acute phase of myocardial infarction. The 2022 European guidelines on ventricular arrhythmias recommend implantable cardioverter-defibrillator (ICD) placement for secondary prevention when ventricular fibrillation occurs ≥ 48 hours after the infarct. Yet this recommendation rests on limited evidence. We therefore conduct a multicentre retrospective study to characterise the clinical profile, management, and prognosis of sustained ventricular arrhythmias (ventricular tachycardia and ventricular fibrillation) arising in the acute myocardial infarction setting.
The primary objective of this study is to evaluate post-discharge mortality in patients who develop an arrhythmia either within 48 hours of, or more than 48 hours after, an acute myocardial infarction. Sensitivity analyses will further examine outcomes according to the arrhythmia subtype (ventricular fibrillation vs ventricular tachycardia), the presence of concomitant heart failure, and the myocardial-infarction phenotype (STEMI vs NSTEMI).
All included individuals will be consecutive patients who developed a sustained ventricular arrhythmia during the acute phase of a myocardial infarction between January 1, 2012, and April 14, 2024.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
patients who developed a sustained ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation) during the acute phase of myocardial infarction, i.e., from infarct onset to hospital discharge
Post-discharge mortality
Time frame: through study completion, an average of 2 years
Baseline demographic and clinical characteristics at inclusion
This outcome is the characterization of the study population at baseline, including demographic, and clinical-related variables collected at the time of myocardial infarction.
Time frame: At baseline
Number of participants fot each type of myocardial infarction
Includes revascularization strategy and other therapeutic management measures implemented during the index hospitalization.
Time frame: At baseline
Number of participants with each ventricular arrhythmia characteristic and management strategy during index hospitalization
Descriptive summary of ventricular arrhythmia presentation and in-hospital management, including arrhythmia type, timing of occurrence, recurrence, and therapeutic interventions.
Time frame: At baseline
In-hospital mortality
proportion of patients who die during their hospital stay, before discharge
Time frame: From admission until the date of death or hospital discharge, whichever came first, assessed up to 28 days
Number of participants with wearable cardioverter-defibrillator utilization
Time frame: At baseline
Rate of recurrent myocardial infarction after hospital discharge
Time frame: through study completion, an average of 2 years
Rate of recurrent ventricular arrhythmias after hospital discharge
Time frame: through study completion, an average of 2 years
Rate of defibrillator implantation during hospitalization and after hospital discharge
Time frame: through study completion, an average of 2 years
Number of participants, incidence, characteristics, and management of electrical storms
Time frame: At baseline
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Oct 2026, 15 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ST Elevation Myocardial Infarction →
Poitiers University Hospital →